Argobio is a startup studio dedicated to therapeutics based in Paris launched in March 2021 with 50 M€ funding.

Our goal is to build high-potential innovative biotech companies up to Series A financing, based on promising research projects.
 

Argobio provides financial support and operational excellence to early stage projects :
    

Select early-stage cutting-edge innovations from European academia
 

Structure a collaboration agreement with the research institute
 

Provide financial support and a team of experienced scientists and entrepreneurs to mature the project
 

Create new companies during the incubation phase  

PORTFOLIO

Argobio has built a pipeline of projects
reflecting the diversity of therapeutic indications
and modalities interest.